Latest news : Genentech, Inc.

16/02/15	Fortescue Metals Group Limited Reports Unaudited Consolidated Earnings and Production Results for the Half Year Ended December 31, 2014; Provides Production Guidance for the Full Year of Fiscal 2015; Declares Fully Franked Interim Dividend for the Half Year Ended December 31, 2014, Payable on April 7, 2015	CI
29/11/-1	GENENTECH : profit rises, sales top estimates	RE
29/11/-1	GENENTECH : 3rd-quarter profit rises	RE
29/11/-1	GENENTECH : rejects Roche bid but willing to talk	RE
29/11/-1	GENENTECH : rejects Roche bid	RE
29/11/-1	GENENTECH : Roche buys Genentech for $46.8 billion	RE
29/11/-1	GENENTECH : Roche increases Genentech offer to $45.7 billion	RE
29/11/-1	GENENTECH : gives long-term forecast to fend off Roche	RE
29/11/-1	GENENTECH : to make case for higher purchase price	RE
29/11/-1	GENENTECH : asks shareholders to hold off on Roche bid	RE
29/11/-1	GENENTECH : Roche goes hostile, cuts Genentech bid to $42 billion	RE
29/11/-1	GENENTECH : forecast disappoints	RE
29/11/-1	GENENTECH : profit up, forecast light	RE

20/04/11	Genentech, Inc. : Dalradian Appoints Chief Operating Officer	PU
20/04/11	Genentech, Inc. : Dalradian Appoints Chief Operating Officer	PU
29/11/-1	GENENTECH : Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash	PR
29/11/-1	Genentech : Genentech Announces Resubmission of Supplemental Biologics License Application for Avastin in Combination with Paclitaxel for First-Line Metastatic Breast Cancer	BU
29/11/-1	Genentech : CORRECTING and REPLACING Genentech Announces Expiration of Hart-Scott-Rodino Waiting Period and Completes Acquisition of Tanox	BU

News in other languages: Genentech, Inc.

12/04/16	Roche: la FDA homologue Venetoclax pour traiter une sorte de leucémie
11/04/16	Roche erhält von FDA Zulassung für Venetoclax zur Behandlung von Leukämie-Art
29/11/-1	Genentech : accroît de 7% son résultat net trimestriel.
29/11/-1	Genentech : l'offre de Roche considérée comme insuffisante.
29/11/-1	Genentech : s'envole après l'offre de Roche.

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	-2.33%	-2.09%	+49.88%	+170.51%	1,060B
JOHNSON & JOHNSON	-0.82%	-2.30%	+63.79%	+62.00%	619B
ABBVIE INC.	-0.73%	-4.98%	+28.91%	+82.99%	438B
ROCHE HOLDING AG	+0.33%	-1.17%	+31.07%	+27.09%	333B
NOVARTIS AG	-0.02%	-2.85%	+29.15%	+45.24%	282B
ASTRAZENECA PLC	-3.89%	-11.22%	+22.81%	+27.30%	267B
NOVO NORDISK A/S	+0.66%	-1.42%	-26.59%	-37.71%	218B
AMGEN INC.	-0.06%	-2.88%	+23.07%	+62.33%	196B
GILEAD SCIENCES, INC.	-3.72%	-1.10%	+18.41%	+70.56%	161B
Average	-1.18%	-3.25%	+26.72%	+56.70%	397.1B
Weighted average by Cap.	-1.31%	-2.96%	+36.75%	+83.91%